Bicara Therapeutics Common Stock Current Liabilities
| BCAX Stock | 20.79 0.17 0.81% |
Bicara Therapeutics Common fundamentals help investors to digest information that contributes to Bicara Therapeutics' financial success or failures. It also enables traders to predict the movement of Bicara Stock. The fundamental analysis module provides a way to measure Bicara Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bicara Therapeutics stock.
Total Current Liabilities is likely to rise to about 15.6 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 247.1 M in 2024. Bicara |
Bicara Therapeutics Common Company Current Liabilities Analysis
Bicara Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Bicara Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Bicara Therapeutics is extremely important. It helps to project a fair market value of Bicara Stock properly, considering its historical fundamentals such as Current Liabilities. Since Bicara Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bicara Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bicara Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Bicara Therapeutics Common has a Current Liabilities of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Portfolio File Import Now
Portfolio File ImportQuickly import all of your third-party portfolios from your local drive in csv format |
| All Next | Launch Module |
Bicara Fundamentals
| Current Valuation | 577.25 M | ||||
| Shares Outstanding | 54.39 M | ||||
| Shares Owned By Insiders | 0.42 % | ||||
| Number Of Shares Shorted | 2.07 M | ||||
| Price To Book | 2.15 X | ||||
| EBITDA | (58.3 M) | ||||
| Total Debt | 382.75 M | ||||
| Book Value Per Share | (5.10) X | ||||
| Earnings Per Share | (3.75) X | ||||
| Market Capitalization | 1.1 B | ||||
| Total Asset | 233.98 M | ||||
| Retained Earnings | (153.02 M) | ||||
| Working Capital | 215.99 M | ||||
| Net Asset | 233.98 M |
About Bicara Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bicara Therapeutics Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bicara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bicara Therapeutics Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.